CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 578045-578116 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T39397","span":{"begin":0,"end":71},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"MLT can be considered in immunotherapy as an adjunct to IL-2 treatment."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T344","span":{"begin":0,"end":71},"obj":"Sentence"}],"text":"MLT can be considered in immunotherapy as an adjunct to IL-2 treatment."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5467","span":{"begin":0,"end":3},"obj":"Disease"}],"attributes":[{"id":"A5467","pred":"mondo_id","subj":"T5467","obj":"http://purl.obolibrary.org/obo/MONDO_0018735"}],"text":"MLT can be considered in immunotherapy as an adjunct to IL-2 treatment."}